➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
Baxter
Johnson and Johnson

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Marizomib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Marizomib?

Marizomib is an investigational drug.

There have been 10 clinical trials for Marizomib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2018.

The most common disease conditions in clinical trials are Glioma, Neoplasms, Plasma Cell, and Glioblastoma. The leading clinical trial sponsors are Triphase Research and Development I Corporation, Celgene, and National Cancer Institute (NCI).

There are three hundred and twenty-three US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Marizomib
TitleSponsorPhase
Phase I Study of Marizomib + Panobinostat for Children With DIPGCelgenePhase 1
Phase I Study of Marizomib + Panobinostat for Children With DIPGSecura BioPhase 1
Phase I Study of Marizomib + Panobinostat for Children With DIPGDana-Farber Cancer InstitutePhase 1

See all Marizomib clinical trials

Clinical Trial Summary for Marizomib

Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib

See all Marizomib clinical trials

US Patents for Marizomib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Marizomib   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
Marizomib   Start Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Marizomib   Start Trial Methods and compositions for inhibition of Ras ARAXES PHARMA LLC (San Diego, CA)   Start Trial
Marizomib   Start Trial Salt formulations for the fermentation of marine microorganisms Celgene International II Sarl (Couvet, CH)   Start Trial
Marizomib   Start Trial Anti-tigit antibodies and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Marizomib

Drugname Country Document Number Estimated Expiration Related US Patent
Marizomib Australia AU2011279250 2030-07-12   Start Trial
Marizomib Australia AU2012249401 2030-07-12   Start Trial
Marizomib Australia AU2012249419 2030-07-12   Start Trial
Marizomib Australia AU2012249493 2030-07-12   Start Trial
Marizomib Australia AU2012249537 2030-07-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.